Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Chunlu Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7280-8776; OpenAlex author ID A5085085373. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 21

  1. Time to reclassify? The prognostic value of radiologic splenic vessel involvement in resectable pancreatic ductal adenocarcinoma of the body and tail: a system… Co-author DOI 10.1097/js9.0000000000003927↗
  2. The function of microRNA related to cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.bcp.2025.116849↗
  3. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes. Last author DOI 10.1016/j.ijbiomac.2024.134517↗
  4. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma. Last author DOI 10.1097/cad.0000000000001545↗
  5. Clusterin is upregulated by erastin, a ferroptosis inducer and exerts cytoprotective effects in pancreatic adenocarcinoma cells. Last author DOI 10.1097/cad.0000000000001561↗
  6. Remnant Pancreas Volume Affects New-Onset Impaired Glucose Homeostasis Secondary to Pancreatic Cancer. First author DOI 10.3390/biomedicines12081653↗
  7. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective… Co-author DOI 10.1002/cam4.5779↗
  8. Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm12030756↗
  9. Elevated Bile Acid Is Associated with Worsened Impaired Glucose Homeostasis in Pancreatic Ductal Adenocarcinoma Patients with Extrahepatic Cholestasis through … First author DOI 10.3390/jcm12062352↗
  10. Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v15.i8.1703↗
  11. The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/gs-21-859↗
  12. Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis. Co-author DOI 10.4251/wjgo.v14.i10.1903↗
  13. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study. Co-author DOI 10.1097/md.0000000000019327↗
  14. MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-020-1146-x↗
  15. Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. Co-author DOI 10.1186/s12893-019-0537-1↗
  16. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. Co-author DOI 10.1371/journal.pone.0226726↗
  17. Recurrence and survival after surgery for pancreatic cancer with or without acute pancreatitis. Co-author DOI 10.3748/wjg.v25.i39.6006↗
  18. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8th edition of… Last author DOI 10.3748/wjg.v25.i46.6752↗
  19. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. Co-author DOI 10.1016/j.yexcr.2017.10.033↗
  20. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Stud… Co-author DOI 10.1097/md.0000000000002936↗
  21. Deleted in liver cancer-1 inhibits cell growth and tumorigenicity in human pancreatic cancer. First author DOI 10.3892/ol.2013.1415↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhenjiang Zheng · 11 shared papers, 2013–2025 · strength 1.87
  2. Yonghua Chen · 8 shared papers, 2019–2024 · strength 1.60
  3. Xubao Liu · 9 shared papers, 2013–2024 · strength 1.35
  4. Xu-Bao Liu · 6 shared papers, 2017–2026 · strength 1.08
  5. Qingquan Tan · 4 shared papers, 2020–2026 · strength 0.92
  6. Yonghua Chen · 5 shared papers, 2019–2023 · strength 0.74
  7. Xu-Bao Liu · 4 shared papers, 2019–2024 · strength 0.69
  8. Nengwen Ke · 5 shared papers, 2016–2023 · strength 0.65
  9. Xing Wang · 2 shared papers, 2024–2026 · strength 0.59
  10. Xing Wang · 3 shared papers, 2019–2023 · strength 0.55
  11. Jie Yang · 2 shared papers, 2023–2024 · strength 0.48
  12. Yichen Li · 2 shared papers, 2024 · strength 0.47
  13. Epiphane K. Silli · 2 shared papers, 2024–2025 · strength 0.38
  14. Ziying Yao · 1 shared paper, 2026 · strength 0.33
  15. Xing Wang · 2 shared papers, 2020–2023 · strength 0.33
  16. Junjie Xiong · 3 shared papers, 2016–2022 · strength 0.29
  17. Hao Zhang · 2 shared papers, 2019–2020 · strength 0.24
  18. Yonghua Chen · 1 shared paper, 2023 · strength 0.22
  19. Guanhua Chen · 1 shared paper, 2023 · strength 0.22
  20. Xiaoding Shen · 1 shared paper, 2023 · strength 0.20
  21. Jia Chen · 1 shared paper, 2025 · strength 0.20
  22. Ying Wang · 1 shared paper, 2025 · strength 0.20
  23. Yaohui Fang · 1 shared paper, 2025 · strength 0.20
  24. Rui Wang · 1 shared paper, 2023 · strength 0.19
  25. Haoqi Zhang · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.